Kiralis Technologies

Company Overview

Snapshot

Founded in September 2018 by Eyal Capua, Kiralis Technologies operated with 1–10 employees. The company raised $3M across one funding round from Grove Ventures. In September 2018, Kiralis Technologies secured seed funding, marking a significant early milestone in its development.

Business overview

Kiralis Technologies develops commercial-level applications for separating chiral molecules with high purity and repeatability. The company's core technology leverages chiral-induced spin selectivity (CISS), a phenomenon discovered by Professor Naaman and Professor Paltiel, to separate enantiomers in racemic mixtures using a magnetic field. Kiralis Technologies targets various markets, including pharmaceuticals, pesticides, herbicides, flavors, and fragrances, operating within the Health Tech & Life Sciences sector.

Company Intelligence Q&A

What is Kiralis Technologies' primary focus?

Kiralis Technologies focuses on developing commercial-level applications for separating chiral molecules, aiming to achieve high-purity, repeatable products from racemic solutions.

Who are the founders of Kiralis Technologies?

Kiralis Technologies was co-founded by Eyal Capua, who serves as the CTO.

When was Kiralis Technologies founded?

Kiralis Technologies was founded in September 2018.

What is the core technology behind Kiralis Technologies' separation process?

The core technology is based on chiral-induced spin selectivity (CISS), which exploits the CISS effect to separate enantiomers in a racemic mixture through the application of a magnetic field.

What markets does Kiralis Technologies target?

Kiralis Technologies targets racemic solutions in various markets, including pharmaceutical, pesticide, herbicide, flavor, and fragrance industries.